Deep Learning-Enabled Exploration of Predictive Signatures in a Multicenter Retrospective and Prospective Observational Study Allowing the Analysis of the Aggregation of Multimodal Clinical, Biological, Genomic and Radiomics Data Associated With the Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms DEEP-Lung-IV
- Sponsors Sophia Bioscience
- 21 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 15 Apr 2024 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2024.